Treatment of Ampicillin and Cefazolin-Resistant E. coli Diverticular Abscess with Augmentin
Augmentin (amoxicillin-clavulanate) is likely effective for treating a diverticular abscess caused by E. coli resistant to ampicillin and cefazolin, as the addition of clavulanic acid overcomes most common E. coli beta-lactamase resistance mechanisms that cause ampicillin resistance. However, this assumes the resistance is due to beta-lactamase production rather than other mechanisms, and formal susceptibility testing should guide definitive therapy.
Microbiologic Rationale
The key distinction is that ampicillin resistance in E. coli is typically mediated by beta-lactamase production, which clavulanic acid effectively inhibits. 1, 2
Laboratory studies demonstrate that significantly more ampicillin-resistant E. coli isolates are susceptible to amoxicillin-clavulanate compared to ampicillin alone, with one study showing 86.9% susceptibility to amoxicillin-clavulanate versus near-universal resistance to ampicillin-sulbactam among ampicillin-resistant E. coli 1
Clavulanic acid is a potent beta-lactamase inhibitor that restores activity against penicillinase-producing E. coli strains, with approximately one-third of E. coli strains showing significantly greater susceptibility to Augmentin compared to ampicillin alone 2, 3
The "RRS" and "RRI" phenotypes of E. coli (resistant to amoxicillin, susceptible to cephalosporins) that produce penicillinases emerge as very susceptible to amoxicillin-clavulanate 4
Guideline-Based Treatment Recommendations
For mild-to-moderate community-acquired diverticular abscesses, amoxicillin-clavulanate is explicitly recommended as first-line therapy by current guidelines. 5, 6
The WHO Expert Committee (2024) lists amoxicillin-clavulanate as a first-choice agent for mild-to-moderate intra-abdominal infections 5
The IDSA guidelines specifically note that ampicillin-sulbactam is NOT recommended due to high E. coli resistance rates, but this caveat does not extend to amoxicillin-clavulanate, which demonstrates superior activity 5, 6
For community-acquired infections of mild-to-moderate severity, amoxicillin-clavulanate has a narrower spectrum than alternatives like piperacillin-tazobactam or carbapenems, making it preferable when effective 5
Clinical Context and Abscess Management
The size of the diverticular abscess determines whether antibiotics alone are sufficient or if source control is required. 6
Small abscesses (<3-6 cm) may be treated with antibiotics alone for 7 days 6
Large abscesses (>3-6 cm) require percutaneous drainage combined with antibiotic therapy; antibiotics alone are insufficient 6
If source control is inadequate or delayed, escalation to ertapenem or other broader-spectrum agents should be considered 6
Important Caveats and Pitfalls
Resistance to cefazolin in this E. coli isolate raises concern about the specific resistance mechanism.
If the organism produces an ESBL (extended-spectrum beta-lactamase), amoxicillin-clavulanate will NOT be effective, and a carbapenem (ertapenem, meropenem) is required 5, 6
Cefazolin resistance in E. coli may indicate ESBL production or AmpC beta-lactamase, both of which would render amoxicillin-clavulanate ineffective 5
Formal susceptibility testing should be performed to confirm amoxicillin-clavulanate susceptibility before relying on it as definitive therapy 5, 6
Alternative Regimens if Augmentin is Inappropriate
If the E. coli proves resistant to amoxicillin-clavulanate or ESBL production is suspected, alternative regimens include: 5, 6
Ceftriaxone or cefotaxime plus metronidazole for community-acquired infections 5, 6
Ertapenem for suspected ESBL-producing organisms or inadequate source control 6
Piperacillin-tazobactam or meropenem for severe infections or healthcare-associated cases 5
Ciprofloxacin plus metronidazole as a second-choice option (avoid if local resistance >10-20%) 5, 6
Duration of Therapy
Antibiotic therapy should continue for 4-7 days if adequate source control is achieved. 6
Four days is sufficient in immunocompetent, non-critically ill patients with adequate source control 6
Extend to 7 days in immunocompromised or critically ill patients based on clinical response and inflammatory markers 6
Patients with persistent signs of infection beyond 5-7 days warrant diagnostic imaging to assess for inadequate source control 5